{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:53:10Z","timestamp":1777348390197,"version":"3.51.4"},"reference-count":60,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>ContextIrritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain and altered intestinal habits. The pathophysiology of IBS remains unclear. Recent studies have demonstrated that some IBS patients, especially in diarrhea-predominant IBS (IBS-D), display persistent signs of minor mucosal inflammation and a modified intestinal microflora. The mesalazine has known intestinal anti-inflammatory properties. Saccharomyces boulardii is a probiotic used for a long time in treatment of diarrhea, including infectious diarrhea.ObjectiveEvaluate the effects of mesalazine alone, combined therapy of mesalazine with liophylised Saccharomyces boulardii or alone on symptoms of IBS-D patients.MethodsBased on Rome III criteria, 53 IBS-D patients (18 year or more) were included. To exclude organic diseases all patients underwent colonoscopy, stool culture, serum anti-endomisium antibody, lactose tolerance test and ova and parasite exam. Patients were divided in three groups: mesalazine group (MG) - 20 patients received mesalazine 800 mg t.i.d. for 30 days; mesalazine and Saccharomyces boulardii group (MSbG) - 21 patients received mesalazine 800 mg t.i.d. and Saccharomyces boulardii 200 mg t.i.d. for 30 days and; Saccharomyces boulardii group (SbG) \u2013 12 patients received Sb 200 mg t.i.d. for 30 days. Drugs that might have any effect on intestinal motility or secretion were not allowed. Symptom evaluations at baseline and after treatment were performed by means of a 4-point likert scale including: stool frequency, stool form and consistency (Bristol scale), abdominal pain and distension. Paired t test and Kruskal-Wallis test were used for statistical analyses.ResultsCompared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P&lt;0.0001); MSbG (P&lt;0.0001) and in SbG (P= 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9).ConclusionsThe use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine andSaccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies.<\/jats:p>","DOI":"10.1590\/s0004-28032013000400012","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T02:46:56Z","timestamp":1395715616000},"page":"304-309","source":"Crossref","is-referenced-by-count":10,"title":["TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME WITH MESALAZINE AND\/OR SACCHAROMYCES BOULARDII"],"prefix":"10.1590","volume":"50","author":[{"given":"Mauro","family":"BAFUTTO","sequence":"first","affiliation":[{"name":"Instituto Goiano de Gastroenterologia, Brasil; Universidade Federal de Goi\u00e1s, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Roberto de","family":"ALMEIDA","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayle Vilela","family":"LEITE","sequence":"additional","affiliation":[{"name":"Instituto Goiano de Gastroenterologia, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Bafutto Gomes","family":"COSTA","sequence":"additional","affiliation":[{"name":"Instituto Goiano de Gastroenterologia, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enio Chaves de","family":"OLIVEIRA","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pernambuco, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joffre","family":"RESENDE-FILHO","sequence":"additional","affiliation":[{"name":"Instituto Goiano de Gastroenterologia, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1590\/S0004-28032011000100008","article-title":"Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine","volume":"48","author":"Bafutto M","year":"2011","journal-title":"Arq gastroenterol"},{"issue":"(Suppl 2)","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2004.02036.x","article-title":"New pathophysiological mechanisms in irritable bowel syndrome","volume":"20","author":"Barbara G","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.gastro.2003.11.055","article-title":"Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome","volume":"126","author":"Barbara G","year":"2004","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.gtc.2005.02.007","article-title":"Is irritable bowel syndrome a low-grade inflammatory bowel disease?","volume":"34","author":"Bercik P","year":"2005","journal-title":"Gastroenterol Clin N Am"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s001340050367","article-title":"Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial","volume":"23","author":"Bleichner G","year":"1997","journal-title":"Intensive Care Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1046\/j.1365-2036.1999.00652.x","article-title":"Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?","volume":"13","author":"Bus PJ","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1203\/00006450-198602000-00020","article-title":"Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii","volume":"20","author":"Buts JP","year":"1986","journal-title":"Pediatr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1203\/00006450-199410000-00019","article-title":"Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines","volume":"36","author":"Buts JP","year":"1994","journal-title":"Pediatr Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement of pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri M","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/IAI.67.1.302-307.1999","article-title":"Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa","volume":"67","author":"Castagliuolo I","year":"1999","journal-title":"Infect Immun"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/gast.2002.33579","article-title":"Activation of the mucosal immune system in irritable bowel syndrome","volume":"122","author":"Chadwick VS","year":"2002","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2036.2009.04041.x","article-title":"Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study","volume":"30","author":"Corinaldezi R","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ajg.2008.94","article-title":"Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms","volume":"104","author":"Cremon C","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1128\/IAI.68.10.5998-6004.2000","article-title":"Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells","volume":"68","author":"Czerucka D","year":"2000","journal-title":"Infect Immun"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2003.09.028","article-title":"Relative importance of enterochoromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS","volume":"125","author":"Dunlop SP","year":"2003","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1572-0241.2003.07542.x","article-title":"Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome","volume":"98","author":"Dunlop SP","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1572-0241.2006.00672.x","article-title":"Abnormal intestinal permeability in subgroups of diarrhoea predominant irritable bowel syndromes","volume":"101","author":"Dunlop SP","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1046\/j.1365-2036.2003.01578.x","article-title":"Review article: Oral, modified-release mesalazine formulations-proprietary versus generic","volume":"17","author":"Forbes A","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF01300753","article-title":"Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid","volume":"36","author":"Fox CC","year":"1991","journal-title":"Dig Dis Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"G259","DOI":"10.1152\/ajpgi.2000.278.2.G259","article-title":"Inflammation-induced impairment of enteric nerve function in nematode-infected mice is macrophage dependent","volume":"278","author":"Galeazzi F","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1023\/A:1005588911207","article-title":"Saccharomyces boulardii in maintenance treatment of Crohn's disease","volume":"45","author":"Guslandi M","year":"2000","journal-title":"Dig Dis Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00042737-200306000-00017","article-title":"A pilot trial of Saccharomyces boulardii in ulcerative colitis","volume":"15","author":"Guslandi M","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.44.3.400","article-title":"The role of psychological and biological factors in post-infective gut dysfunction","volume":"44","author":"Gwee KA","year":"1999","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/gut.52.4.523","article-title":"Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome","volume":"52","author":"Gwee KA","year":"2003","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3748\/wjg.v10.i3.309","article-title":"Key role of mast cells and their major secretory products in inflammatory bowel disease","volume":"10","author":"He SH","year":"2004","journal-title":"World J Gastroenterol"},{"key":"ref26","first-page":"541","article-title":"Mast cells in inflammatory conditions of the gastrointestinal tract","volume":"37","author":"Hiatt RB","year":"1962","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200106143442407","article-title":"The irritable bowel syndrome","volume":"344","author":"Horwitz BJ","year":"2001","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4269\/ajtmh.2008.78.214","article-title":"Effect of Saccharomyces boulardiiin the Treatment of Acute Watery Diarrhea in Myanmar Children: A Randomized Controlled Study","volume":"78","author":"Htwe K","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1023\/A:1018924820333","article-title":"Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers","volume":"10","author":"Klein SM","year":"1993","journal-title":"Pharm Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2036.2005.02356.x","article-title":"Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial","volume":"21","author":"Kotowska M","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.bjp.0702937","article-title":"Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine","volume":"128","author":"Liptay S","year":"1999","journal-title":"Br J Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1111\/j.1572-0241.2000.03342.x","article-title":"Progress in understanding the mechanisms of action of 5-aminosalicylic acid","volume":"95","author":"MacDermott RP","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"ref33","first-page":"77","article-title":"Treatment of irritable bowel syndrome withSaccharomyces boulardii: a double-blind, placebo-controlled-study","volume":"12","author":"Maupas J","year":"1983","journal-title":"Med Chir Dig"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1572-0241.2006.00465.x","article-title":"Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease","volume":"101","author":"McFarland LV","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tmaid.2005.10.003","article-title":"Meta-analysis of probiotics for the prevention of traveler's diarrhea","volume":"5","author":"McFarland LV","year":"2007","journal-title":"Travel Med Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner SA","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"G599","DOI":"10.1152\/ajpgi.00391.2007","article-title":"Saccharomyces boulardii interferes with Shigella pathogenesis by post-invasion signaling events","volume":"294","author":"Mumy KL","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2004.08.057","article-title":"Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome","volume":"127","author":"Murray CD","year":"2004","journal-title":"Gastroenterology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2982.2000.00221.x","article-title":"Increased mast cells in the irritable bowel syndrome","volume":"12","author":"O'Sullivan M","year":"2000","journal-title":"Neurogastroenterol Motil"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/147323000703500204","article-title":"Effect of Saccharomyces boulardiiin children with acute gastroenteritis and its relationship to the immune response","volume":"35","author":"Ozkan TB","year":"2007","journal-title":"J Int Med Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3346\/jkms.2003.18.2.204","article-title":"Acitivated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome","volume":"18","author":"Park CH","year":"2003","journal-title":"J Korean Med Sci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2982.2006.00771.x","article-title":"Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome","volume":"18","author":"Park JH","year":"2006","journal-title":"Neurogastroenterol Motil"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-2000-135","article-title":"Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel","volume":"32","author":"Reinacher-Schick A","year":"2000","journal-title":"Endoscopy"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-2672.2000.01128.x","article-title":"Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice","volume":"89","author":"Rodrigues AC","year":"2000","journal-title":"J Appl Microbiol"},{"key":"ref45","first-page":"64","author":"Saint-Marc T","year":"1991"},{"key":"ref46","first-page":"847","article-title":"Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases","volume":"60","author":"Salzmann JL","year":"1989","journal-title":"Lab Invest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn W J","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/j.1875-9114.1994.tb02829.x","article-title":"Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease","volume":"14","author":"Small RE","year":"1994","journal-title":"Pharmacotherapy"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2006.02.080","article-title":"Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression","volume":"343","author":"Sougioultzis S","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","article-title":"Increased rectal mucosal enteroendocrine cells, T lymphcytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome","volume":"47","author":"Spiller RC","year":"2000","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0016-5085(89)90627-6","article-title":"Mast cells are closely apposed to nerves in the human gastrointestinal mucosa","volume":"97","author":"Stead RH","year":"1989","journal-title":"Gastroenterology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(02)09712-X","article-title":"Irritable bowel syndrome: a little understood organic bowel disease?","volume":"360","author":"Talley NJ","year":"2002","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/mpat.2002.0495","article-title":"Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii","volume":"32","author":"Tasteyre A","year":"2002","journal-title":"Microb Pathog"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/gast.2002.37059","article-title":"Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome","volume":"123","author":"Tornblom H","year":"2002","journal-title":"Gastroenterology"},{"key":"ref55","first-page":"3124","article-title":"Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties","volume":"46","author":"Tromm A","year":"1999","journal-title":"Hepatogastroenterol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI5823","article-title":"IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system","volume":"103","author":"Xia Y","year":"1999","journal-title":"J Clin Invest"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl C","year":"1998","journal-title":"J Clin Invest"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/gut.2003.021154","article-title":"Bacillary dysentery as a causative factor of irritable syndrome and its pathogenesis","volume":"53","author":"Wang LH","year":"2004","journal-title":"Gut"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1053\/gast.2000.19458","article-title":"Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta","volume":"119","author":"Weber CK","year":"2000","journal-title":"Gastroenterology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2982.2000.00221.x","article-title":"Terminal ileal mucosal mast cells in irritable bowel syndrome","volume":"12","author":"Weston AP","year":"2000","journal-title":"Neurogastroenterol Motil"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v50n4\/0004-2803-ag-50-04-304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T09:30:19Z","timestamp":1716629419000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032013000400304&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0004-28032013000400304"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032013000400012","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}